<div id="container">

  <div class="section">
    <div class="headline"></div>
    <h2 class="sub_headline">Optistavin was evaluated for safety and tolerability in over 2,700 patients across 3 clinical trials.<sup>1</sup></h2>
    <ul class="patient_info">
	    <li>Age 66</li> 
	    <li>Prostate cancer diagnosed 2 years ago</li>
	    <li>Recent rise in PSA levels</li>
    </ul>
    <div class="patient" id="john"></div>
    <div class="graph"></div>
    <p class="graph_footer">Not an actual patient. For illustration purposes only.</p>

    <p class="fair_use">Most frequently occurring adverse events grades 3-5: diarrhea 4%, 2%; colitis 3%, 2%; fatigue 6%, 4% for Optistavin and placebo respectively.</p>
  </div>

  <div class="section" id="beverley">
    <div class="headline"></div>
    <h2 class="sub_headline">Optistavin was evaluated for safety and tolerability in over 2,700 patients across 3 clinical trials.<sup>1</sup></h2>
    <ul class="patient_info">
	    <li>Age 68</li> 
	    <li>Smoker for 20+ years</li>
	    <li>Unresectable STage III disease</li>
    </ul>
    <div class="patient" id="beverley"></div>


    <div class="graph" ></div>
    <p class="graph_footer">Not an actual patient. For illustration purposes only.</p>

    <p class="fair_use">Most frequently occurring adverse events grades 3-5: neutropenia 17%, 23%; fatigue 13%, 16%; hypertension 2%, 8% for control + chemo and Optistavin + chemo, respectively.</p>
  </div>




</div>
<script>
  isa.unlock_scroll();
</script>

